BioTech 365

NOVEMBER 2, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Legend’s status put on hold as FDA delays Janssen-partnered CAR-T decision.Legend’s status put on hold as FDA delays Janssen-partnered CAR-T decision badams Tue, 11/02/2021 – 04:23 from … Continue reading →

Research 40

Research 40

BioTech 365

NOVEMBER 3, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Turning CAR-T tech against solid tumors by targeting protein fragments in cancer cells.Turning CAR-T tech against solid tumors by targeting protein fragments in cancer cells aliu Wed, … Continue reading →

Protein 40

Protein Research 40

BioTech 365

APRIL 14, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Bluebird, PsiOxus show oncolytic virus boosts CAR-T in solid tumors.Bluebird, PsiOxus show oncolytic virus boosts CAR-T in solid tumors ntaylor Wed, 04/14/2021 – 08:44 from FierceBiotech: Biotech … Continue reading (..)

Research 40

Research 40

BioTech 365

JANUARY 11, 2022

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Regeneron, 2seventy name the target of their first solid tumor CAR-T, aim for 2023 IND.Regeneron, 2seventy name the target of their first solid tumor CAR-T, aim for … Continue reading →

Research 40

Research 40

BioTech 365

AUGUST 31, 2020

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Sotio licences Unum Therapeutics’ CAR-T cell portfolio. from European Biotechnology – first and foremost in European biotech [link].

Research 40

Research 40

BioTech 365

FEBRUARY 10, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: After ditching Editas, AbbVie taps Caribou for new CRISPR, CAR-T pact.After ditching Editas, AbbVie taps Caribou for new CRISPR, CAR-T pact badams Wed, 02/10/2021 – 08:31 from … Continue reading →

Research 40

Research 40

BioTech 365

NOVEMBER 12, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: SITC: Cellectis’ off-the-shelf CAR-T for pancreatic cancer and mesothelioma shows activity in mice.SITC: Cellectis’ off-the-shelf CAR-T for pancreatic cancer and mesothelioma shows activity in mice arlene.weintraub (..)

Research 40

Research 40

BioTech 365

OCTOBER 21, 2020

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: CRISPR stock slides as CAR-T death overshadows signs of efficacy.CRISPR stock slides as CAR-T death overshadows signs of efficacy ntaylor Wed, 10/21/2020 – 08:56 from FierceBiotech: Biotech … Continue reading → (..)

Research 40

Research 40

BioTech 365

APRIL 29, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Is combined recognition the solution for CAR-T therapy against glioblastoma, other solid tumors? Is combined recognition the solution for CAR-T therapy against glioblastoma, other solid tumors?

Research 40

Research 40

BioTech 365

NOVEMBER 8, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Blackstone bets on Autolus’ CD19 CAR-T in $250M deal, clearing path to pivotal readout in 2022.Blackstone

Research 40

Research 40

BioTech 365

OCTOBER 8, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: FDA stops all Allogene’s CAR-T trials over safety scare, raising questions about future of gene editing.FDA stops all Allogene’s CAR-T trials over safety scare, raising questions about … Continue reading →

Gene Editing 40

Gene Editing Gene Trials Research 40

BioTech 365

FEBRUARY 4, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: New study points to why CAR-T therapy may fail in some lymphoma patients.New study points to why CAR-T therapy may fail in some lymphoma patients aliu Thu, … Continue reading →

Research 40

Research 40

BioTech 365

SEPTEMBER 2, 2020

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Virus combo makes solid tumors vulnerable to CAR-T attack in mice.Virus combo makes solid tumors vulnerable to CAR-T attack in mice arlene.weintraub Wed, 09/02/2020 – 09:14 from … Continue reading →

Research 40

Research 40

BioTech 365

APRIL 5, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Legend Biotech, J&J finish off rolling submission for CAR-T hopeful, approach finish line.Legend Biotech, J&J finish off rolling submission for CAR-T hopeful, approach finish line badams Mon, … Continue reading (..)

Research 40

Research 40

BioTech 365

FEBRUARY 12, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Bristol Myers Squibb pens $1.3B biobucks pact with Molecular Templates, axes Celgene CAR-T asset.Bristol Myers Squibb pens $1.3B

Research 40

Research 40

BioTech 365

NOVEMBER 10, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Takeda-backed Poseida puts off-the-shelf CAR-T in its basket, places autologous therapy back on the shelf.Takeda-backed Poseida puts off-the-shelf CAR-T in its basket, places autologous therapy back on … Continue reading (..)

Research 40

Research 40

BioTech 365

FEBRUARY 26, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Oncolytics Bio’s cancer-killing virus arms CAR-T cells to attack solid tumors in mice.Oncolytics Bio’s cancer-killing virus arms CAR-T cells to attack solid tumors in mice aliu Fri, … Continue reading → (..)

Research 40

Research 40

BioTech 365

AUGUST 18, 2020

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Poseida shares plunge after death in solid tumor CAR-T trial, clinical hold.Poseida shares plunge after death in solid tumor CAR-T trial, clinical hold badams Tue, 08/18/2020 – … Continue reading →

Trials 40

Trials Research 40

BioTech 365

MAY 13, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Autolus’ CD19 CAR-T posts 100% complete response rate, zero grade 3 CRS in small lymphoma trial.Autolus’ CD19 CAR-T posts 100% complete response rate, zero grade 3 CRS … Continue reading →

Trials 40

Trials Research 40

BioTech 365

JANUARY 5, 2022

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Intellia bags option on autoimmune CAR-T prospect, handing Kyverna rights to use CRISPR tech to create off-the-shelf cell therapy .Intellia

Research 40

Research 40

BioTech 365

SEPTEMBER 2, 2020

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Orca Bio, Lyell Immunopharma pen new pact to open up CAR-T for solid tumors.Orca Bio, Lyell Immunopharma pen new pact to open up CAR-T for solid tumors … Continue reading →

Research 40

Research 40

BioTech 365

DECEMBER 7, 2020

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: ASH: Allogene’s off-the-shelf CAR-T posts 60% response rate in fiercely competitive BCMA field.ASH: Allogene’s off-the-shelf CAR-T posts 60% response rate in fiercely competitive BCMA field ntaylor Mon, … Continue (..)

Research 40

Research 40

BioTech 365

OCTOBER 30, 2020

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Bellicum shares nose-dive on poor CAR-T data, program pause—company axes 79% of staffers.Bellicum shares nose-dive on poor CAR-T data, program pause—company axes 79% of staffers badams Fri, … Continue reading →

Research 40

Research 40

BioTech 365

JANUARY 4, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Putting the ‘STING’ on CAR-T cells to turn them against breast cancer and other solid tumors.Putting the ‘STING’ on CAR-T cells to turn them against breast cancer … Continue reading →

Research 40

Research 40

Drug Discovery World

MARCH 22, 2024

News round-up for 18-22 March by DDW Digital Content Editor Diana Spencer. 175M financing will support development of in vivo CAR-T therapies Biotechnology company Capstan Therapeutics has raised $175 million in an oversubscribed Series B financing.

Gene Therapy 52

Gene Therapy In-Vivo FDA Approval Drugs 52

BioTech 365

AUGUST 31, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: A year after a death and accompanying trial hold, Poseida hopes for reprieve with early solid tumor CAR-T data.A year after a death and accompanying trial hold, … Continue reading →

Trials 40

Trials Research 40

Pharma Times

JULY 14, 2023

CAR-T cell therapy being researched among patients with relapsed or refractory B cell non-Hodgkin lymphoma - News - PharmaTimes

Research 108

Research 108

Drug Discovery World

APRIL 26, 2024

News round-up for 22-26 April by DDW Digital Content Editor Diana Spencer. The leading news story this week has been the launch of a new clinical trial in the UK for a melanoma personalised mRNA cancer vaccine, but there have been a number of other interesting developments in cancer drug discovery.

Clinical Trials 52

Clinical Trials Clinical Trials Drugs Bacteria 52

Drug Discovery World

AUGUST 11, 2023

News round-up for by DDW Digital Content Editor Diana Spencer. The news headlines this week reflect the level of interest in cell & gene therapies (CGT) in the sector, particularly CAR-T, but also the importance of research collaborations to bring these therapies to patients.

Gene Therapy 52

Gene Therapy Drugs Clinical Trials Clinical Trials 52

Drug Discovery World

DECEMBER 15, 2023

News round-up for 11-15 December by DDW Digital Content Editor Diana Spencer. Real-world evidence supports use of CAR-T therapies in blood cancers Real-world evidence from the French DESCAR-T registry has shown an overall response rate (ORR) of 76.9% and complete response rate (CR) of 57.7%

Drugs 52

Drugs Clinical Trials Clinical Trials Manufacturing 52

Drug Discovery World

APRIL 29, 2024

The leading news story this week has been the launch of a new clinical trial in the UK for a melanoma personalised mRNA cancer vaccine, but there have been a number of other interesting developments in cancer drug discovery. The latest episode of the DDW Highlights podcast is now available to listen to below.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

Drug Discovery World

SEPTEMBER 29, 2023

News round-up for 25-29 September by DDW Digital Content Editor Diana Spencer. The top stories: €27.3M to advance monoclonal antibody for autoimmune diseases AbolerIS Pharma has raised €27.3 million in a Series A financing led by Caixa Capital Risc and co-led by Sound Bioventures and Newton Biocapital.

In-Vivo 52

In-Vivo Drugs Antibody Clinical Trials 52

Drug Discovery World

AUGUST 11, 2023

GenScript Biotech and T-MAXIMUM Biotech have formed a strategic collaboration to develop T-MAXIMUM’s CAR-T cell therapy using GenScript’s CRISPR nucleic acid reagents. GenScript will provide various CRISPR reagents to support the development of the universal CAR-T products from discovery to commercialisation.

Reagent 52

Reagent Development Gene Editing Production 52

Drug Discovery World

FEBRUARY 2, 2024

News round-up for 29 January – 2 February by DDW Digital Content Editor Diana Spencer. Phase I trial for first-in-class bispecific antibody for cancer Onward Therapeutics has announced the Phase I clinical trial of OT-A201, a first-in-class bispecific antibody targeting two immune checkpoints is in progress.

Drugs 52

Drugs Antibody Clinical Trials Clinical Trials 52

Pharmaceutical Technology

JANUARY 27, 2023

The chimeric antigen receptor T-cell (CAR-T) therapy axicabtagene ciloleucel has been recommended for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL) in adult patients who have previously received two or more lines of systemic therapy.

Gene Therapy 147

Gene Therapy Clinical Trials Clinical Trials Gene 147

Drug Discovery World

AUGUST 14, 2023

The news headlines this week reflect the level of interest in cell & gene therapies (CGT) in the sector, particularly CAR-T, but also the importance of research collaborations to bring these therapies to patients.

Gene Therapy 52

Gene Therapy Gene Drugs Marketing 52

Drug Discovery World

DECEMBER 19, 2023

Our news highlights this week focus on haematology, thanks in part to a number of key announcements at the 65th American Society for Hematology meeting (ASH) Annual Meeting, including real-world evidence on the use of CAR-T therapies in blood cancers and new data for myeloma and lymphoma treatments.

Drugs 59

Drugs Research 59